The Roche–Zealand amylin obesity drug, petrelintide, delivered up to 10.7% weight loss in a phase 2 obesity trial with a "placebo-like tolerability" profile, the companies say.
Roche's experimental amylin shot, petrelintide, acquired nearly a year ago as part of a $1.65 billion deal with Zealand Pharma, showed a differentiated "placebo-like tolerability" profile in a mid-st… [+4002 chars]
